Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell

Patent metadata

Field	Value
Publication number	US-10723997-B2
Application number	US-201716091656-A
Country	US
Kind code	B2
Filing date	Mar 30, 2017
Priority date	Apr 15, 2016
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.

First claim

What is claimed is:

1. A method for treating a chronic pulmonary disease, comprising:
administering to a subject in need thereof an effective amount of exosomes derived from thrombin-treated stem cells,
wherein the chronic pulmonary disease is bronchopulmonary dysplasia.

2. The method according to claim 1 , wherein the stem cells are stem cells selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells, and amniotic epithelial cells.

3. The method according to claim 2 , wherein the mesenchymal stem cells are derived from an umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, an amniotic membrane, or a placenta.

4. The method according to claim 1 , wherein the exosomes are administered into an airway or a blood vessel of a subject.

5. The method according to claim 1 , further comprising:
administering to a subject in need thereof an effective amount of an adjuvant component selected from the group consisting of a culture medium, a cytokine, a growth factor, and a gene.

6. The method according to claim 1 , wherein the exosomes are increased in the expression of a growth factor, an immune regulatory factor, an antioxidant factor, or a regenerative factor.

7. The method according to claim 6 , wherein the growth factor comprises brain-derived neurotropic factor (BDNF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), or vascular endothelial growth factor (VEGF).

Assignees

• Samsung Life Public Welfare Foundation

Inventors

• Chang Yun Sil
• Park Won Soon
• Sung Dong Kyung
• Ahn So Yoon

Classifications

• A61P11/00 Primary

  Drugs for disorders of the respiratory system · CPC title

• A61K35/35

  Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39) · CPC title

• A61K35/34

  Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44) · CPC title

• A61K35/30

  Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

• A61K35/51

  Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title